Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, SpainBarcelona, Catalonia, Spain
Disclosure information not submitted.
Paper 61 - INSIGHT: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF RIPRETINIB VS SUNITINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR PREVIOUSLY TREATED WITH IMATINIB WITH KIT EXON 11+17/18 MUTATIONS
Saturday, November 4, 20239:00 AM – 10:00 AM
Paper 62 - PEAK STUDY: A PHASE 3, RANDOMIZED, OPEN-LABEL MULTICENTER CLINICAL STUDY OF BEZUCLASTINIB (CGT9486) AND SUNITINIB COMBINATION VERSUS SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST)
Paper 72 - GENOMIC EVOLUTION OF RESISTANCE IN GASTROINTESTINAL STROMAL TUMOR: KIT AP/AL MUTATIONS ARE A KEY MECHANISM OF KINASE-INHIBITOR ESCAPE
Saturday, November 4, 202311:30 AM – 1:00 PM
